Biotech Values

[DewDiligence]

MYNZ IPOs 2.0M shares @$5.00:

https://www.globenewswire.com/news-release/2021/11/04/2328142/0/en/Mainz-Biomed-N-V-Announces-Pricing-of-Initial-Public-Offering.html

Mainz Biomed N.V. develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.

The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process to be launched in the fourth quarter of 2021 for U.S. regulatory approval.

Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

$10M of gross proceeds is a micro-molecular IPO!

I don’t know how ColoAlert will compete with EXAS’ Cologuard.